![]() |
IMIX Biopharma, Inc. (IMMX) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Immix Biopharma, Inc. (IMMX) Bundle
Möchten Sie den inneren Wert von IMIX Biopharma, Inc. beurteilen? Unser (IMMX) DCF-Taschenrechner integriert reale Daten mit umfangreichen Anpassungsfunktionen, sodass Sie Ihre Prognosen verfeinern und Ihre Anlagestrategien verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | -89.5 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | -100 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -.8 | -.5 | -1.3 | -8.2 | -16.1 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 9.18 | 100 | 81.84 | 81.84 | 81.84 | 81.84 | 81.84 |
Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | -0.00238502 | 100 | 80 | 80 | 80 | 80 | 80 |
EBIT | -.8 | -.5 | -1.4 | -8.2 | -16.1 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 9.18 | 100 | 81.84 | 81.84 | 81.84 | 81.84 | 81.84 |
Total Cash | .7 | .4 | 17.6 | 13.4 | 17.5 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | .1 | .0 | .3 | 1.2 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | -0.28565 | 100 | 79.94 | 79.94 | 79.94 | 79.94 | 79.94 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | .2 | .3 | .1 | .1 | 1.4 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | -0.15983 | 100 | 79.97 | 79.97 | 79.97 | 79.97 | 79.97 |
Capital Expenditure | .0 | .0 | .0 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 0 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 |
EBITAT | -.9 | -.5 | -1.4 | -8.2 | -16.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -.8 | -.4 | -1.4 | -8.5 | -15.7 | -.3 | .0 | .0 | .0 | .0 |
WACC, % | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 |
PV UFCF | ||||||||||
SUM PV UFCF | -.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | 0 | |||||||||
Net Debt | -18 | |||||||||
Equity Value | 17 | |||||||||
Diluted Shares Outstanding, MM | 17 | |||||||||
Equity Value Per Share | 1.00 |
What You Will Get
- Real Immix Biopharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Immix Biopharma, Inc. (IMMX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Immix Biopharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to Immix Biopharma, Inc. (IMMX).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for your financial assessments.
Key Features
- Comprehensive IMMX Data: Pre-filled with Immix Biopharma's historical financials and future growth projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investment plans.
- Adaptive Valuation Framework: Instant updates to Net Present Value (NPV) and intrinsic value based on your tailored inputs.
- Scenario Analysis: Develop various forecasting scenarios to explore different valuation possibilities.
- User-Centric Interface: Intuitive, organized, and suitable for both industry veterans and newcomers.
How It Works
- Download: Get the comprehensive Excel file featuring Immix Biopharma, Inc.'s (IMMX) financial data.
- Customize: Tailor your forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and evaluate outcomes immediately.
- Make Decisions: Leverage the valuation results to inform your investment strategy.
Why Choose This Calculator for Immix Biopharma, Inc. (IMMX)?
- Designed for Industry Experts: A sophisticated tool tailored for biopharma analysts, investors, and researchers.
- Comprehensive Data: Immix Biopharma’s historical and projected financials preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically calculates intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the calculation process.
Who Should Use This Product?
- Investors: Accurately assess Immix Biopharma’s fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immix Biopharma, Inc. (IMMX).
- Consultants: Efficiently customize the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biopharma companies.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the life sciences field.
What the Immix Biopharma, Inc. (IMMX) Template Contains
- Comprehensive DCF Model: Editable template featuring in-depth valuation calculations tailored for biopharmaceutical analysis.
- Real-World Data: Immix Biopharma’s historical and projected financials preloaded for thorough examination.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns to provide deeper insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to the biopharma sector.
- Dashboard with Visual Outputs: Interactive charts and tables for clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.